{
    "nct_id": "NCT06000787",
    "official_title": "Molecular Characterization Trial for the Harvard/UCSF ROBIN Center: Radiation Oncology At the Interface of Pediatric Cancer Biology and Data Science",
    "inclusion_criteria": "* Enrollment on one of the following clinical trials:\n\n  * Pacific Pediatric Neuro-Oncology Consortium PNOC023: Open label Phase 1 and Target Validation study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Brain Tumors (NCT04732065) - Arm A or B (Key Eligibility Criteria: Newly diagnosed DMG, Age ≥ 2 years, If on corticosteroids, on a stable or decreasing dose for ≥ 3 days prior to baseline MRI scan, Karnofsky ≥ 50 for age >16 or Lansky ≥ 50 for age ≤ 16, No known disorder that affects the immune system or uncontrolled infection)\n  * Children's Oncology Group ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NCT03126916) - Arm B (Key Eligibility Criteria: Diagnosis of high-risk neuroblastoma (INRG Stage M with MYCN amplification or age > 547 days, INRG Stage MS with MYCN amplification, INRG Stage L2 with MYCN amplification, or progression to Stage M in certain groups), Age ≥ 1 and ≤ 30 years at diagnosis, No prior systemic or radiation therapy, with certain exceptions, No contraindication to targeted radiopharmaceutical therapy)\n* Tumor tissue confirmation of malignancy\n* Adequate bone marrow, renal, liver and neurologic function\n* Availability of tumor tissue, blood and/or CSF biospecimens\nHealthy volunteers allowed",
    "exclusion_criteria": "* Pregnancy or breastfeeding\n* Inability to follow the procedures of the study",
    "miscellaneous_criteria": ""
}